Milestone Scientific Receives ANVISA Approval To Market CompuFlo Epidural System In Brazil; Aims To Expand Addressable Market With Technological Advantages; Brazil Conducts 4-5M Epidural Procedures Annually
Portfolio Pulse from Benzinga Newsdesk
Milestone Scientific has received ANVISA approval to market its CompuFlo Epidural System in Brazil. The company aims to expand its addressable market by leveraging the technological advantages of its system. Brazil conducts 4-5 million epidural procedures annually.
June 18, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Milestone Scientific has received regulatory approval from ANVISA to market its CompuFlo Epidural System in Brazil. This approval allows the company to tap into a market that conducts 4-5 million epidural procedures annually, potentially increasing its revenue and market presence.
The ANVISA approval is a significant regulatory milestone that allows Milestone Scientific to enter the Brazilian market, which conducts a substantial number of epidural procedures annually. This could lead to increased sales and revenue for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100